|
2025-01-27 |
2025-01-24 |
V
Vente
|
Wall Brett A.
EVP & Pres Neuroscience
Dirigeant
|
12 437
-23.3%
90,00
1 119 330 USD
|
12 437
-23.3%
|
90,00
|
1 119 330 USD
|
|
|
2025-01-10 |
2025-01-08 |
V
Vente
|
Wall Brett A.
EVP & Pres Neuroscience
Dirigeant
|
3 000
-6.9%
80,41
241 230 USD
|
3 000
-6.9%
|
80,41
|
241 230 USD
|
|
|
2025-01-10 |
2025-01-08 |
V
Vente
|
Wall Brett A.
EVP & Pres Neuroscience
Dirigeant
|
6 850
-13.5%
80,41
550 809 USD
|
6 850
-13.5%
|
80,41
|
550 809 USD
|
|
|
2024-06-11 |
2024-06-07 |
V
Vente
|
Martha Geoffrey
Chairman and CEO
Administrateur exécutif
|
1 594
-1.1%
83,82
133 609 USD
|
1 594
-1.1%
|
83,82
|
133 609 USD
|
|
|
2024-06-11 |
2024-06-07 |
V
Vente
|
Martha Geoffrey
Chairman and CEO
Administrateur exécutif
|
17 519
-10.8%
83,76
1 467 391 USD
|
17 519
-10.8%
|
83,76
|
1 467 391 USD
|
|
|
2024-04-09 |
2024-04-08 |
V
Vente
|
Marinaro Michael
EVP & President, Surgical OU
Dirigeant
|
854
-3.0%
83,14
71 002 USD
|
854
-3.0%
|
83,14
|
71 002 USD
|
|
|
2024-02-23 |
2024-02-21 |
V
Vente
|
Salmon Sean
EVP & President Cardiovascular
Dirigeant
|
16 035
-24.9%
85,12
1 364 899 USD
|
16 035
-24.9%
|
85,12
|
1 364 899 USD
|
|
|
2024-02-23 |
2024-02-21 |
V
Vente
|
Salmon Sean
EVP & President Cardiovascular
Dirigeant
|
13 066
-16.9%
85,15
1 112 570 USD
|
13 066
-16.9%
|
85,15
|
1 112 570 USD
|
|
|
2024-02-23 |
2024-02-21 |
V
Vente
|
Salmon Sean
EVP & President Cardiovascular
Dirigeant
|
1 594
-2.0%
85,06
135 586 USD
|
1 594
-2.0%
|
85,06
|
135 586 USD
|
|
|
2023-12-20 |
2023-12-19 |
VP
Vente planifiée
|
Wall Brett A.
EVP & Pres Neuroscience
Dirigeant
|
4 997
-14.7%
82,17
410 603 USD
|
4 997
-14.7%
|
82,17
|
410 603 USD
|
|
|
2023-08-25 |
2023-08-23 |
V
Vente
|
Smith Gregory L
EVP Global Ops & Supply Chain
Dirigeant
|
10 000
-17.6%
83,84
838 400 USD
|
10 000
-17.6%
|
83,84
|
838 400 USD
|
|
|
2023-08-16 |
2023-08-14 |
VP
Vente planifiée
|
Wall Brett A.
EVP & Pres Neuroscience
Dirigeant
|
1 000
-2.9%
83,38
83 380 USD
|
1 000
-2.9%
|
83,38
|
83 380 USD
|
|
|
2023-08-07 |
2023-08-04 |
VP
Vente planifiée
|
Marinaro Michael
EVP & President, Surgical OU
Dirigeant
|
1 352
-4.5%
84,11
113 717 USD
|
1 352
-4.5%
|
84,11
|
113 717 USD
|
|
|
2023-07-18 |
2023-07-14 |
VP
Vente planifiée
|
Wall Brett A.
EVP & Pres Neuroscience
Dirigeant
|
2 000
-7.7%
87,97
175 940 USD
|
2 000
-7.7%
|
87,97
|
175 940 USD
|
|
|
2023-07-12 |
2023-07-10 |
V
Vente
|
TEN HOEDT ROB
EVP and Pres. Global Regions
Dirigeant
|
3 706
-7.8%
86,58
320 865 USD
|
3 706
-7.8%
|
86,58
|
320 865 USD
|
|
|
2023-07-12 |
2023-07-10 |
V
Vente
|
TEN HOEDT ROB
EVP and Pres. Global Regions
Dirigeant
|
1 808
-4.0%
86,59
156 555 USD
|
1 808
-4.0%
|
86,59
|
156 555 USD
|
|
|
2022-12-16 |
2022-12-13 |
V
Vente
|
Salmon Sean
EVP & President Cardiovascular
Dirigeant
|
16 631
-31.5%
80,50
1 338 736 USD
|
16 631
-31.5%
|
80,50
|
1 338 736 USD
|
|
|
2022-10-17 |
2022-10-14 |
V
Vente
|
TEN HOEDT ROB
EVP and Pres. Global Regions
Dirigeant
|
2 404
-5.2%
81,54
196 015 USD
|
2 404
-5.2%
|
81,54
|
196 015 USD
|
|
|
2022-03-21 |
2022-03-18 |
VP
Vente planifiée
|
PARKHILL KAREN L
EVP & Chief Financial Officer
Dirigeant
|
682
-1.9%
110,00
75 020 USD
|
682
-1.9%
|
110,00
|
75 020 USD
|
|
|
2022-03-14 |
2022-03-11 |
V
Vente
|
Surface Carol A
SVP, Chief HR Officer
Dirigeant
|
6 000
-17.4%
105,30
631 800 USD
|
6 000
-17.4%
|
105,30
|
631 800 USD
|
|
|
2021-12-17 |
2021-12-16 |
A
Achat
|
ANDERSON RICHARD H
Administrateur non-exécutif
|
5 010
+4.8%
103,26
517 333 USD
|
5 010
+4.8%
|
103,26
|
517 333 USD
|
|
|
2021-12-07 |
2021-12-06 |
VP
Vente planifiée
|
PARKHILL KAREN L
EVP & Chief Financial Officer
Dirigeant
|
682
-1.9%
110,00
75 020 USD
|
682
-1.9%
|
110,00
|
75 020 USD
|
|
|
2021-10-01 |
2021-09-30 |
VP
Vente planifiée
|
Lerman Bradley E
SVP General Counsel & Corp Sec
Dirigeant
|
49 147
-50.2%
126,58
6 221 027 USD
|
49 147
-50.2%
|
126,58
|
6 221 027 USD
|
|
|
2021-08-26 |
2021-08-25 |
V
Vente
|
Salmon Sean
EVP & Pres Diabetes/Cardiovasc
Dirigeant
|
7 290
-17.9%
134,09
977 516 USD
|
7 290
-17.9%
|
134,09
|
977 516 USD
|
|
|
2021-08-26 |
2021-08-25 |
V
Vente
|
Salmon Sean
EVP & Pres Diabetes/Cardiovasc
Dirigeant
|
21 129
-38.8%
134,08
2 832 976 USD
|
21 129
-38.8%
|
134,08
|
2 832 976 USD
|
|
|
2021-08-04 |
2021-08-02 |
VP
Vente planifiée
|
Lerman Bradley E
SVP General Counsel & Corp Sec
Dirigeant
|
4 000
-7.7%
131,52
526 080 USD
|
4 000
-7.7%
|
131,52
|
526 080 USD
|
|
|
2021-06-17 |
2021-06-15 |
VP
Vente planifiée
|
PARKHILL KAREN L
EVP & Chief Financial Officer
Dirigeant
|
605
-0.7%
124,47
75 304 USD
|
605
-0.7%
|
124,47
|
75 304 USD
|
|
|
2021-06-02 |
2021-06-01 |
VP
Vente planifiée
|
Wall Brett A.
EVP & Pres Neuroscience
Dirigeant
|
2 473
-10.3%
128,07
316 717 USD
|
2 473
-10.3%
|
128,07
|
316 717 USD
|
|
|
2021-06-01 |
2021-05-28 |
VP
Vente planifiée
|
Liddicoat John R
EVP & President of Americas
Dirigeant
|
34 656
-44.9%
126,65
4 389 182 USD
|
34 656
-44.9%
|
126,65
|
4 389 182 USD
|
|
|
2021-04-07 |
2021-04-05 |
VP
Vente planifiée
|
Martha Geoffrey
CEO
Administrateur exécutif
|
9 308
-10.2%
118,83
1 106 070 USD
|
9 308
-10.2%
|
118,83
|
1 106 070 USD
|
|
|
2021-04-07 |
2021-04-05 |
VP
Vente planifiée
|
Martha Geoffrey
CEO
Administrateur exécutif
|
2 404
-2.9%
118,83
285 667 USD
|
2 404
-2.9%
|
118,83
|
285 667 USD
|
|
|
2021-03-16 |
2021-03-15 |
VP
Vente planifiée
|
PARKHILL KAREN L
EVP & Chief Financial Officer
Dirigeant
|
632
-0.7%
119,12
75 284 USD
|
632
-0.7%
|
119,12
|
75 284 USD
|
|
|
2021-03-03 |
2021-03-02 |
V
Vente
|
TEN HOEDT ROB
EVP & President EMEA
Dirigeant
|
7 168
-14.1%
117,98
845 681 USD
|
7 168
-14.1%
|
117,98
|
845 681 USD
|
|
|
2020-12-30 |
2020-12-28 |
V
Vente
|
Surface Carol A
SVP, Chief HR Officer
Dirigeant
|
15 000
-30.5%
114,90
1 723 500 USD
|
15 000
-30.5%
|
114,90
|
1 723 500 USD
|
|
|
2020-12-23 |
2020-12-22 |
V
Vente
|
Lerman Bradley E
SVP General Counsel & Corp Sec
Dirigeant
|
2 605
-4.8%
115,56
301 034 USD
|
2 605
-4.8%
|
115,56
|
301 034 USD
|
|
|
2020-12-21 |
2020-12-18 |
V
Vente
|
WHITE ROBERT JOHN
EVP & Pres. Medical Surgical
Dirigeant
|
10 930
-19.6%
115,46
1 261 978 USD
|
10 930
-19.6%
|
115,46
|
1 261 978 USD
|
|
|
2020-12-16 |
2020-12-15 |
VP
Vente planifiée
|
PARKHILL KAREN L
EVP & Chief Financial Officer
Dirigeant
|
670
-0.8%
114,33
76 601 USD
|
670
-0.8%
|
114,33
|
76 601 USD
|
|
|
2020-11-10 |
2020-11-09 |
VP
Vente planifiée
|
Lerman Bradley E
SVP General Counsel & Corp Sec
Dirigeant
|
20 715
-27.7%
113,13
2 343 488 USD
|
20 715
-27.7%
|
113,13
|
2 343 488 USD
|
|
|
2020-10-14 |
2020-10-09 |
V
Vente
|
ISHRAK OMAR
Executive Chairman
Administrateur exécutif
|
763
-0.1%
108,40
82 709 USD
|
763
-0.1%
|
108,40
|
82 709 USD
|
|
|
2020-10-09 |
2020-10-08 |
VP
Vente planifiée
|
Lerman Bradley E
SVP General Counsel & Corp Sec
Dirigeant
|
797
-1.4%
110,00
87 670 USD
|
797
-1.4%
|
110,00
|
87 670 USD
|
|
|
2020-10-09 |
2020-10-08 |
VP
Vente planifiée
|
Lerman Bradley E
SVP General Counsel & Corp Sec
Dirigeant
|
19 917
-26.8%
110,00
2 190 870 USD
|
19 917
-26.8%
|
110,00
|
2 190 870 USD
|
|
|
2020-10-09 |
2020-10-08 |
A
Achat
|
ANDERSON RICHARD H
Administrateur non-exécutif
|
4 607
+4.7%
108,52
499 952 USD
|
4 607
+4.7%
|
108,52
|
499 952 USD
|
|
|
2020-09-25 |
2020-09-23 |
VP
Vente planifiée
|
TEN HOEDT ROB
EVP & President EMEA
Dirigeant
|
9 584
-18.1%
104,34
999 995 USD
|
9 584
-18.1%
|
104,34
|
999 995 USD
|
|
|
2020-09-16 |
2020-09-15 |
VP
Vente planifiée
|
PARKHILL KAREN L
EVP & Chief Financial Officer
Dirigeant
|
702
-0.8%
107,78
75 662 USD
|
702
-0.8%
|
107,78
|
75 662 USD
|
|
|
2020-09-11 |
2020-09-09 |
VP
Vente planifiée
|
TEN HOEDT ROB
EVP & President EMEA
Dirigeant
|
9 563
-15.3%
105,05
1 004 593 USD
|
9 563
-15.3%
|
105,05
|
1 004 593 USD
|
|
|
2020-06-02 |
2020-05-29 |
V
Vente
|
Surface Carol A
SVP, Chief HR Officer
Dirigeant
|
2 000
-4.0%
97,72
195 440 USD
|
2 000
-4.0%
|
97,72
|
195 440 USD
|
|
|
2020-02-24 |
2020-02-20 |
A
Achat
|
ISHRAK OMAR
Chairman & CEO
Administrateur exécutif
|
8 771
+1.5%
113,68
997 087 USD
|
8 771
+1.5%
|
113,68
|
997 087 USD
|
|
|
2019-12-26 |
2019-12-24 |
V
Vente
|
Kuntz Richard
SVP & Chief Medical & Science
Dirigeant
|
38 558
-35.2%
113,56
4 378 646 USD
|
38 558
-35.2%
|
113,56
|
4 378 646 USD
|
|
|
2019-12-26 |
2019-12-24 |
V
Vente
|
Kuntz Richard
SVP & Chief Medical & Science
Dirigeant
|
1 808
-2.5%
113,66
205 497 USD
|
1 808
-2.5%
|
113,66
|
205 497 USD
|
|
|
2019-12-26 |
2019-12-24 |
V
Vente
|
Kuntz Richard
SVP & Chief Medical & Science
Dirigeant
|
2 404
-3.3%
113,60
273 094 USD
|
2 404
-3.3%
|
113,60
|
273 094 USD
|
|
|
2019-12-26 |
2019-12-24 |
V
Vente
|
Kuntz Richard
SVP & Chief Medical & Science
Dirigeant
|
3 019
-4.1%
113,63
343 049 USD
|
3 019
-4.1%
|
113,63
|
343 049 USD
|
|
|
2019-12-26 |
2019-12-24 |
V
Vente
|
Kuntz Richard
SVP & Chief Medical & Science
Dirigeant
|
5 067
-6.4%
113,64
575 814 USD
|
5 067
-6.4%
|
113,64
|
575 814 USD
|
|
|
2019-12-09 |
2019-12-06 |
A
Achat
|
ANDERSON RICHARD H
Administrateur non-exécutif
|
5 000
+5.5%
113,29
566 450 USD
|
5 000
+5.5%
|
113,29
|
566 450 USD
|
|
|
2019-12-03 |
2019-12-02 |
VP
Vente planifiée
|
WHITE ROBERT JOHN
EVP & President MITG
Dirigeant
|
12 583
-19.5%
110,97
1 396 373 USD
|
12 583
-19.5%
|
110,97
|
1 396 373 USD
|
|
|
2019-12-03 |
2019-12-02 |
VP
Vente planifiée
|
WHITE ROBERT JOHN
EVP & President MITG
Dirigeant
|
12 859
-16.6%
110,28
1 418 091 USD
|
12 859
-16.6%
|
110,28
|
1 418 091 USD
|
|
|
2019-12-03 |
2019-12-02 |
VP
Vente planifiée
|
WHITE ROBERT JOHN
EVP & President MITG
Dirigeant
|
13 240
-14.6%
110,97
1 469 283 USD
|
13 240
-14.6%
|
110,97
|
1 469 283 USD
|
|
|
2019-12-03 |
2019-12-02 |
VP
Vente planifiée
|
WHITE ROBERT JOHN
EVP & President MITG
Dirigeant
|
13 484
-12.9%
110,29
1 487 083 USD
|
13 484
-12.9%
|
110,29
|
1 487 083 USD
|
|
|
2019-11-18 |
2019-11-15 |
VP
Vente planifiée
|
COYLE MICHAEL J
EVP & Group Pres, Cardiac&Vasc
Dirigeant
|
3 797
-2.0%
112,07
425 530 USD
|
3 797
-2.0%
|
112,07
|
425 530 USD
|
|
|
2019-11-18 |
2019-11-15 |
VP
Vente planifiée
|
COYLE MICHAEL J
EVP & Group Pres, Cardiac&Vasc
Dirigeant
|
25 710
-11.8%
111,31
2 861 883 USD
|
25 710
-11.8%
|
111,31
|
2 861 883 USD
|
|
|
2019-11-18 |
2019-11-15 |
VP
Vente planifiée
|
COYLE MICHAEL J
EVP & Group Pres, Cardiac&Vasc
Dirigeant
|
7 367
-3.3%
110,59
814 680 USD
|
7 367
-3.3%
|
110,59
|
814 680 USD
|
|
|
2019-11-15 |
2019-11-14 |
VP
Vente planifiée
|
COYLE MICHAEL J
EVP & Group Pres, Cardiac&Vasc
Dirigeant
|
1 202
-0.6%
109,95
132 160 USD
|
1 202
-0.6%
|
109,95
|
132 160 USD
|
|
|
2019-11-15 |
2019-11-14 |
VP
Vente planifiée
|
COYLE MICHAEL J
EVP & Group Pres, Cardiac&Vasc
Dirigeant
|
900
-0.5%
109,52
98 571 USD
|
900
-0.5%
|
109,52
|
98 571 USD
|
|
|
2019-11-04 |
2019-11-01 |
VP
Vente planifiée
|
WHITE ROBERT JOHN
EVP & President MITG
Dirigeant
|
1 964
-3.6%
109,66
215 378 USD
|
1 964
-3.6%
|
109,66
|
215 378 USD
|
|
|
2019-11-04 |
2019-11-01 |
VP
Vente planifiée
|
WHITE ROBERT JOHN
EVP & President MITG
Dirigeant
|
3 349
-5.8%
109,11
365 419 USD
|
3 349
-5.8%
|
109,11
|
365 419 USD
|
|
|
2019-11-04 |
2019-11-01 |
VP
Vente planifiée
|
WHITE ROBERT JOHN
EVP & President MITG
Dirigeant
|
14 662
-22.0%
109,67
1 607 938 USD
|
14 662
-22.0%
|
109,67
|
1 607 938 USD
|
|
|
2019-11-04 |
2019-11-01 |
VP
Vente planifiée
|
WHITE ROBERT JOHN
EVP & President MITG
Dirigeant
|
28 428
-29.9%
109,11
3 101 722 USD
|
28 428
-29.9%
|
109,11
|
3 101 722 USD
|
|
|
2019-11-04 |
2019-11-01 |
VP
Vente planifiée
|
WHITE ROBERT JOHN
EVP & President MITG
Dirigeant
|
3 762
-6.1%
109,66
412 537 USD
|
3 762
-6.1%
|
109,66
|
412 537 USD
|
|
|
2019-11-04 |
2019-11-01 |
VP
Vente planifiée
|
COYLE MICHAEL J
EVP & Group Pres, Cardiac&Vasc
Dirigeant
|
1 202
-0.6%
109,50
131 619 USD
|
1 202
-0.6%
|
109,50
|
131 619 USD
|
|
|
2019-11-04 |
2019-11-01 |
VP
Vente planifiée
|
COYLE MICHAEL J
EVP & Group Pres, Cardiac&Vasc
Dirigeant
|
37 774
-16.7%
109,50
4 136 253 USD
|
37 774
-16.7%
|
109,50
|
4 136 253 USD
|
|
|
2019-09-30 |
2019-09-27 |
VP
Vente planifiée
|
Kuntz Richard
SVP & Chief Medical & Science
|
100
-0.1%
108,21
10 821 USD
|
100
-0.1%
|
108,21
|
10 821 USD
|
|
|
2019-09-30 |
2019-09-27 |
VP
Vente planifiée
|
Kuntz Richard
SVP & Chief Medical & Science
|
21 325
-21.3%
107,51
2 292 672 USD
|
21 325
-21.3%
|
107,51
|
2 292 672 USD
|
|
|
2019-09-12 |
2019-09-10 |
VP
Vente planifiée
|
HAKAMI HOOMAN
EVP & Group President Diabetes
|
423
-1.4%
107,22
45 354 USD
|
423
-1.4%
|
107,22
|
45 354 USD
|
|
|
2019-09-12 |
2019-09-10 |
VP
Vente planifiée
|
HAKAMI HOOMAN
EVP & Group President Diabetes
|
14 121
-31.5%
107,41
1 516 765 USD
|
14 121
-31.5%
|
107,41
|
1 516 765 USD
|
|
|
2019-09-12 |
2019-09-10 |
VP
Vente planifiée
|
HAKAMI HOOMAN
EVP & Group President Diabetes
|
595
-1.9%
107,22
63 796 USD
|
595
-1.9%
|
107,22
|
63 796 USD
|
|
|
2019-09-12 |
2019-09-10 |
VP
Vente planifiée
|
HAKAMI HOOMAN
EVP & Group President Diabetes
|
19 054
-38.2%
107,41
2 046 666 USD
|
19 054
-38.2%
|
107,41
|
2 046 666 USD
|
|
